To that matter, some potential molecules such as GLP-1 receptor agonists, used to treat T2D, or other molecules have yet to be further studied in order to judge their efficiency on NAFLD/NASH. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.